IL Dong Pharmaceutical일동제약
249420 · KOSPI · ₩249420 · 일동제약
₩12,580▲ ₩10 (0.08%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩567B | ₩615B | ₩601B | ₩638B | ₩560B |
| Cost of sales | ₩347B | ₩381B | ₩387B | ₩401B | ₩341B |
| Gross profit | ₩220B | ₩233B | ₩214B | ₩236B | ₩219B |
| Operating income | ₩19B | ₩13B | −₩54B | −₩73B | −₩56B |
| Net income | ₩24B | −₩12B | −₩81B | −₩142B | −₩101B |
| Net income to shareholders | ₩28B | −₩4.6B | −₩79B | −₩142B | −₩100B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩573B | ₩589B | ₩611B | ₩656B | ₩709B |
| Current assets | ₩222B | ₩247B | ₩236B | ₩282B | ₩302B |
| Cash and equivalents | ₩65B | ₩72B | ₩53B | ₩52B | ₩136B |
| Total liabilities | ₩334B | ₩430B | ₩437B | ₩458B | ₩548B |
| Current liabilities | ₩231B | ₩276B | ₩314B | ₩316B | ₩364B |
| Borrowings | ₩125B | ₩213B | — | ₩262B | ₩354B |
| Total equity | ₩240B | ₩159B | ₩174B | ₩198B | ₩161B |
| Shareholders' equity | ₩246B | ₩161B | ₩170B | ₩191B | ₩153B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩19B | ₩28B | −₩37B | −₩54B | −₩11B |
| Capital spending | ₩14B | ₩11B | ₩13B | ₩12B | ₩15B |
| Free cash flow | ₩5.3B | ₩18B | −₩50B | −₩65B | −₩26B |
| Dividends paid | ₩60M | ₩77M | −₩160M | ₩120M | — |
Consolidated where available. Amounts in won.
Also known as: IL Dong Pharmaceutical / 일동제약 / 249420 / KRX:249420
Source: KRX statistical information